Welcome to our dedicated page for Biomind Labs news (Ticker: BMNDF), a resource for investors and traders seeking the latest updates and insights on Biomind Labs stock.
Biomind Labs Inc. (BMNDF) generates news centered on clinical research, psychedelic-based CNS drug development, and nanotechnology-enabled pharmaceutical formulations. As a clinical-stage biopharmaceutical and biotech research and development company, Biomind uses its news releases to report progress on its proprietary candidates, regulatory milestones and scientific findings related to psychiatric and neurological conditions.
Recent updates highlight BMND08, a 5-MeO-DMT-based sublingual formulation for depression and anxiety in Alzheimer’s disease and Alzheimer’s-related mood disorders. The company has reported Phase 2 clinical trial results for BMND08, including non-psychedelic dosing regimens, mood improvements and preliminary cognitive findings in early stages of mild to moderate Alzheimer’s-related cognitive impairment. Subsequent news has described the transition of BMND08 into FDA-directed activities using a proprietary nano-formulation drug-delivery platform designed to support commercial-stage clinical trials in neuropsychiatric and neurodegenerative disorders.
Biomind’s news flow also covers its broader pipeline, such as BMND01 DMT inhaled and intramuscular formulations, BMND02 5-MeO-DMT nasal thermosensitive gel, BMND06 targeting obesity through neurological and inflammatory pathways, and BMND07 5-MeO-DMT synthesis for pharmaceutical-grade API. The company reports preclinical toxicology and in vitro data, nano pharmaceutical formulations of DMT and 5-MeO-DMT, and mescaline-related research, along with updates on its intellectual property portfolio and patent applications.
Investors and observers can use the Biomind Labs news page on Stock Titan to follow disclosures about clinical trial stages, IND-related developments, continuous disclosure filings with Canadian regulators, and corporate governance events such as board appointments and shareholder meeting outcomes.
Biomind Labs announced that CEO Alejandro Antalich will debate at the PSYCH Symposium in London on May 11, 2022. The symposium focuses on the potential of psychedelic healthcare. Antalich highlighted the importance of this discussion and expressed respect for UK Prime Minister Boris Johnson's consideration of psychedelic drug legalization. The company aims to develop pharmaceuticals using psychedelic molecules to address mental health disorders, emphasizing the need for further research to aid nearly one billion affected individuals.
Biomind Labs Inc. has announced the start of dose administration in a Phase I/IIa clinical trial for BMND01, a novel inhaled DMT formulation aimed at treating treatment-resistant depression. This unique trial, led by Dr. Dráulio Araújo, is the first of its kind globally to test an inhaled DMT drug and is being conducted at the University Hospital Onofre Lopes. The study will eventually include psychedelic-naïve patients. Initial dosing in health volunteers is expected to complete within four months.
Biomind Labs Inc. (OTC: BMNDF) announced its participation in the PSYCH Symposium on May 11, 2022, at The National Gallery in London. CEO Alejandro Antalich emphasized the event's significance in the psychedelic industry, aiming to foster discussions on mental health treatment advancements. The UK is becoming a leader in psychedelic research, advocating for greater collaboration and regulatory analysis. Biomind Labs focuses on developing novel pharmaceutical formulations of psychedelic compounds to address psychiatric and neurological disorders, promoting accessible treatments for patients.
Biomind Labs Inc., a leading biotech firm focused on endogenous tryptamines for mental health, announces CEO Alejandro Antalich and Dr. Dráulio Barros de Araújo will present at the Benzinga Psychedelics Capital Conference on April 19, 2022, in Miami. Attendees will gain insights into Biomind's diverse portfolio, including the BMND06 clinical trial and advances in DMT research, targeting depression. The Company aims to develop affordable psychedelic treatments through innovative drug delivery systems.
Biomind Labs Inc. has announced the launch of a commercial clinical trial for its proprietary drug candidate, BMND06, which is based on mescaline, a psychedelic molecule. This trial is a significant step towards the registration of its product, Triptax® M, with the FDA and the European Medicines Agency. The trial aims to address inflammation linked to depression, showcasing a strategic expansion beyond the company's previous focus on DMT and 5-MeO-DMT. The trials will be conducted in partnership with the esteemed Albert Einstein Hospital, adhering to high ethical and quality standards.
Biomind Labs Inc. has officially opened a new clinical psychedelic research facility at the University Hospital Onofre Lopes. This facility will enhance the company's clinical research capabilities, particularly for its Phase II clinical trial utilizing inhaled DMT to address treatment-resistant depression. CEO Alejandro Antalich emphasized that this development strengthens Biomind's pioneering position in the psychedelic landscape, aiming to innovate treatment methods for mental health disorders. The company focuses on using tryptamines like DMT, 5-MeO-DMT, and mescaline for psychiatric conditions.